Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2011

Satoh Hironori, Inoue Akira, Kobayashi Kunihiko, Maemondo Makoto, Oizumi Satoshi, Isobe Hiroshi, Gemma Akihiko, Saijo Yasuo, Yoshizawa Hirohisa, Hagiwara Koichi, Nukiwa Toshihiro

Abstract excerpt

INTRODUCTION: Although standard schedule of gefitinib was the administration of 250 mg tablet every day, many patients need dose reduction because of toxicities. However, the efficacy of such low-dose gefitinib for patients with epidermal growth factor receptor-mutated non-small cell lung cancer has rarely been evaluated. METHODS: A post hoc comparison of the efficacy (response rate and survival) in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Dose-Response Relationship, Drug

Share to Gefitinib

Share to Neoplasm Staging

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 21681118
DOI: 10.1097/JTO.0b013e31821d43a8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.PMID 21681118Read ↗

Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area.Semantic proximity Read ↗

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.Semantic proximity Read ↗

The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.Semantic proximity Read ↗

A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.Semantic proximity Read ↗

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.Semantic proximity Read ↗

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report.Semantic proximity Read ↗

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.Semantic proximity Read ↗

The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer.Semantic proximity Read ↗

Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).Semantic proximity Read ↗

Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: A prospective, multicenter, dose-modification study.Semantic proximity Read ↗

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).Semantic proximity Read ↗

[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.